Garrison Bradford Associates Inc buys $7,385,418 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Garrison Bradford Associates Inc scooped up 6,070 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 73,670 shares of Celgene Corporation which is valued at $7,385,418.Celgene Corporation makes up approximately 8.61% of Garrison Bradford Associates Inc’s portfolio.

Celgene Corporation closed down -1.46 points or -1.44% at $100.25 with 37,28,230 shares getting traded on Friday. Post opening the session at $100.72, the shares hit an intraday low of $99.27 and an intraday high of $102.11 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Thompson Davis reduced its stake in CELG by selling 641 shares or 41.98% in the most recent quarter. The Hedge Fund company now holds 886 shares of CELG which is valued at $88,822. Celgene Corporation makes up approx 0.13% of Thompson Davis’s portfolio.Calamos Wealth Management reduced its stake in CELG by selling 1,797 shares or 6.53% in the most recent quarter. The Hedge Fund company now holds 25,737 shares of CELG which is valued at $2,661,463. Celgene Corporation makes up approx 0.58% of Calamos Wealth Management’s portfolio. Jfs Wealth Advisors added CELG to its portfolio by purchasing 24 company shares during the most recent quarter which is valued at $2,482. Ims Capital Management added CELG to its portfolio by purchasing 8,835 company shares during the most recent quarter which is valued at $913,627. Celgene Corporation makes up approx 1.10% of Ims Capital Management’s portfolio.Cape Cod Five Cents Savings Bank reduced its stake in CELG by selling 286 shares or 8.66% in the most recent quarter. The Hedge Fund company now holds 3,017 shares of CELG which is valued at $311,988. Celgene Corporation makes up approx 0.06% of Cape Cod Five Cents Savings Bank’s portfolio.

On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.